RIPK1 Inhibitor Therapy in Neurodegeneration

Overview

<table class=“infobox infobox-therapeutic”> <tr> <th class=“infobox-header” colspan=“2”>RIPK1 Inhibitor Therapy in Neurodegeneration</th> </tr> <tr> <td class=“label”>Drug</td> <td>Target</td> </tr> <tr> <td class=“label”>Necrostatin-1</td> <td>RIPK1</td> </tr> <tr> <td class=“label”>Necrostatin-1s</td> <td>RIPK1</td> </tr> <tr> <td class=“label”>Deguelin</td> <td>RIPK1/PI3K</td> </tr> <tr> <td class=“label”>DQP</td> <td>RIPK1</td> </tr> <tr> <td class=“label”>GSK-2982772</td> <td>RIPK1</td> </tr> <tr> <td class=“label”>Drug</td> <td>Indication</td> </tr> <tr> <td class=“label”>GSK-2982772</td> <td>Psoriasis</td> </tr> <tr> <td class=“label”>GSK-2982772</td> <td>IBD</td> </tr> <tr> <td class=“label”>GSK-2982772</td> <td>RA</td> </tr> </table>

Receptor-Interacting Protein Kinase 1 (RIPK1) is a critical regulator of necroptosis, a form of programmed cell death that contributes to neuronal loss in amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and other neurodegenerative disorders[@galluzzi2022][@yuan2021]. RIPK1 sits at the intersection of cell death and inflammatory signaling, making it an attractive therapeutic target for neurodegeneration where both processes arepathologically elevated[@wang2022].

Necroptosis is a caspase-independent cell death mechanism that involves RIPK1-mediated activation of RIPK3 and MLKL, leading to plasma membrane rupture and release of intracellular inflammatory contents. In neurodegenerative diseases, chronic neuroinflammation triggers necroptotic pathways in neurons and glia, contributing to progressive neuronal loss[@kourtis2023].

This page covers RIPK1 biology, necroptosis mechanism, therapeutic inhibitors, evidence across neurodegenerative diseases, clinical trial status, and future directions.

RIPK1 and Necroptosis Biology

The Necroptosis Pathway

Necroptosis is activated by death receptor ligation (TNF-α, FasL, TRAIL) when caspase-8 activity is inhibited. The pathway involves:

flowchart TD
    A["TNF-alpha / FasL / TRAIL"] --> B["Death Receptor<br/>Activation"]
    B --> C["RIPK1<br/>Autophosphorylation"]
    C --> D["RIPK1-RIPK3<br/>Complex Formation"]
    D --> E["MLKL<br/>Phosphorylation"]
    E --> F["MLKL Oligomerization"]
    F --> G["Plasma Membrane<br/>Permeabilization"]
    G --> H["Necroptotic<br/>Cell Death"]
    G --> I["DAMPs Release"]
    I --> J["Neuroinflammation"]

    K["Caspase-8<br/>Inhibition"] --> C
    L["cIAP1/2<br/>Depletion"] --> C

    style A fill:#0a1929,stroke:#333
    style C fill:#3b1114,stroke:#333
    style H fill:#3b1114,stroke:#333
    style J fill:#3b1114,stroke:#333

RIPK1 Structure and Function

RIPK1 is a serine/threonine kinase with multiple functional domains:

N-terminal kinase domain: Catalytic activity, target of inhibitors
Intermediate domain: RIPK3 interaction
C-terminal death domain: Death receptor interaction

Key functions:

Kinase activity: Drives necroptosis when activated
Scaffold function: Can promote apoptosis independently of kinase activity
Inflammatory signaling: Activates NF-κB and MAPK pathways

RIPK1 in Neurodegeneration

RIPK1 activation in neurodegenerative diseases occurs through:

Neuroinflammation: Elevated TNF-α in AD, PD, ALS brain[@mcquade2022]
Oxidative stress: ROS activates death receptor pathways
Protein aggregation: α-Syn, Aβ, Tau trigger stress responses
Mitochondrial dysfunction: Increases susceptibility to necroptosis

Evidence from postmortem brain:

RIPK1 elevation in AD hippocampus (correlates with tau)[@zhu2023]
RIPK1 in PD substantia nigra dopaminergic neurons[@iannaro2022]
RIPK1 activation in ALS motor cortex and spinal cord[@liu2022]
RIPK1 in HD striatum and cortex

RIPK1 Inhibitors

Drug Candidates

1. Necrostatin-1 (Nec-1)

Mechanism: Allosteric RIPK1 kinase inhibitor
Status: Research use, not clinically approved
Evidence:
- First discovered in 2005 as necroptosis inhibitor
- Neuroprotective in multiple animal models
- Limited brain penetration
- Used extensively in research

2. Necrostatin-1s (Nec-1s)

Mechanism: Stabilized analog of Nec-1
Status: Research compound
Advantages:
- Improved metabolic stability
- Better solubility
- Used in advanced preclinical studies

3. Deguelin

Mechanism: Natural product, RIPK1 inhibitor (also inhibits PI3K)
Status: Investigational
Evidence:
- Neuroprotective in PD models[@lee2021]
- Anti-inflammatory properties
- Cancer chemopreventive agent
- Limited by off-target effects

4. Dimeriquinazolinone (DQP)

Mechanism: RIPK1 kinase inhibitor
Status: Preclinical development
Advantages:
- Brain-penetrant
- Orally bioavailable
- Improved selectivity

5. GSK-2982772 (GSK-772)

Mechanism: Selective RIPK1 inhibitor
Status: Clinical development (Phase 1/2)
Evidence:
- First RIPK1 inhibitor in clinical trials
- Tested in psoriasis, IBD, RA
- Safety profile established
- Potential for CNS applications

6. R-575

Mechanism: RIPK1 inhibitor
Status: Preclinical
Note: Developed for inflammatory diseases

Mechanism of Neuroprotection

RIPK1 inhibitors protect neurons through:

Direct necroptosis blockade: Prevent MLKL activation and membrane permeabilization
Anti-inflammatory effects: Reduce TNF-α-mediated inflammation
Anti-apoptotic effects: Can inhibit caspase-dependent cell death
Microglial modulation: Reduce inflammatory microglial activation

Evidence by Disease

Amyotrophic Lateral Sclerosis

Evidence:

Strong evidence for RIPK1 involvement in ALS[@liu2022]
TNF-α levels elevated in ALS CSF and brain
RIPK1 activation in motor neurons and glia
Postmortem ALS tissue shows RIPK1 and p-MLKL positivity
Correlates with disease severity

Therapeutic Rationale:

Motor neurons are susceptible to necroptosis
Neuroinflammation drives disease progression
Targeting both cell death and inflammation

Preclinical Data:

Nec-1 extends survival in ALS mouse models
Deguelin improves motor function
RIPK1 inhibitors reduce motor neuron loss
Combined with SOD1-targeted approaches

Clinical Status:

GSK-2982772 Phase 1/2 completed (non-neurological indications)
No ALS-specific trials yet
Strong biological rationale for development

Alzheimer’s Disease

Evidence:

RIPK1 elevation in AD brain[@zhu2023]
Co-localization with tau pathology
TNF-α elevation in AD brain and CSF
RIPK1 in microglia surrounding plaques
Correlates with cognitive decline

Therapeutic Rationale:

Chronic neuroinflammation drives progression
Neuronal loss involves necroptosis
May preserve remaining neurons

Preclinical Data:

Nec-1 reduces neuronal loss in AD models
Improves memory in amyloid models
Reduces microglial activation
Combined with anti-amyloid approaches

Clinical Status:

No AD-specific trials yet
Target validation from human tissue
Potential for disease modification

Parkinson’s Disease

Evidence:

RIPK1 in PD substantia nigra[@iannaro2022]
TNF-α elevation in PD brain and CSF
α-Synuclein triggers necroptosis pathway
Postmortem tissue shows RIPK3 activation

Therapeutic Rationale:

Dopaminergic neurons vulnerable to necroptosis
Neuroinflammation is central to PD pathogenesis
May protect remaining neurons

Preclinical Data:

Deguelin protects dopaminergic neurons[@lee2021]
Nec-1 in MPTP model shows neuroprotection
RIPK1 inhibitors reduce neuroinflammation
Combined with LRRK2 inhibitors

Clinical Status:

No PD-specific trials yet
Strong preclinical rationale
Good candidate for clinical development

Huntington’s Disease

Evidence:

Emerging evidence for necroptosis in HD[@ref]
RIPK1 elevation in HD striatum
Mutant huntingtin triggers neuroinflammation
Elevated TNF-α in HD models and patients

Therapeutic Rationale:

Striatal neurons are particularly vulnerable
Protein stress triggers necroptosis
May reduce both cell death and inflammation

Preclinical Data:

RIPK1 inhibitors show efficacy in HD models
Improves behavioral outcomes
Reduces mutant huntingtin toxicity

Clinical Status:

No HD trials yet
Emerging biological rationale
May combine with gene-silencing

CBS/PSP/FTD

Evidence:

Chronic neuroinflammation in 4R-tauopathies
RIPK1 in PSP and CBD brain
TDP-43 pathology triggers necroptosis in FTD
Common inflammatory mechanisms

Therapeutic Rationale:

Neuroinflammation is a shared mechanism
May benefit multiple tauopathies
Addresses both neuroinflammation and cell death

Preclinical Data:

RIPK1 inhibitors in tauopathy models
Reduces neuroinflammation
May improve motor and cognitive function

Clinical Status:

No trials yet
Biological plausibility supports investigation

Comparison of Approaches

Combination Strategies

RIPK1 inhibitors may be combined with:

Anti-inflammatory agents: Synergistic neuroprotection
Anti-aggregation drugs: Address protein pathology
Neurotrophic factors: Support neuron survival
Antioxidants: Counteract oxidative stress
Gene-silencing approaches: Reduce mutant protein

Safety Considerations

Potential Risks

Immunosuppression: RIPK1 inhibition may impair immune function
Infection risk: Necroptosis is defense mechanism
Liver toxicity: Some compounds affect hepatic function
Tumor promotion: Theoretical cancer risk

Monitoring Requirements

Immune function tests
Liver function tests
Neurological assessments
Infection surveillance

Therapeutic Window

Necroptosis inhibition may be safer than general apoptosis inhibition
Partial inhibition may be sufficient for benefit
Temporal targeting (early disease) may reduce risks

Clinical Trial Landscape

Active Studies

GSK-2982772 in inflammatory diseases (Phase 2)
DQP in preclinical development
Other RIPK1 inhibitors in Phase 1

Completed Studies

Challenges

Brain penetration: Many compounds don’t reach CNS
Selectivity: Off-target effects possible
Biomarkers: Need markers for target engagement
Timing: Optimal treatment window unclear

Future Directions

Brain-penetrant RIPK1 inhibitors for CNS
Biomarker development for patient selection
Combination approaches
Earlier intervention

Cross-References

Related Mechanisms

Related Proteins

Related Diseases

Related Therapeutics

Summary

RIPK1 inhibitor therapy represents a promising approach to neurodegenerative disease treatment by targeting necroptosis, a form of programmed cell death that contributes to neuronal loss in ALS, AD, PD, HD, and other disorders. Multiple drug candidates including Necrostatin-1, Deguelin, DQP, and GSK-2982772 have demonstrated neuroprotective effects in preclinical models. While clinical trials in neurodegenerative diseases have not yet begun, the strong biological rationale and established safety profiles from inflammatory disease trials support development. The dual role of RIPK1 in both cell death and inflammation makes it an attractive target for combination approaches. Future directions include brain-penetrant inhibitors, biomarker-driven patient selection, and combination therapies.